LDL trial
A new study confirmed that more intensive lipid-lowering led to atherosclerotic plaque regression in patients who had not been on statins before: see statin intensive plaque regression JAMANetwork2026 in dropbox, or doi:10.1001/jamacardio.2026.4788 Details: --this study was a prespecified analysis of the FLOWPROMOTE study, a randomized clinical trial performed in 3 Danish hospitals that had significant experience in the conduct of coronary CTA (coronary computed tomography angiography) as well as FFR-CT (flow fractional reserve) -- there were initial studies at the time of diagnosis for coronary CTA which was then repeated at 9 and 18 months -- the goal of this study was to assess the association between achieved LDL cholesterol levels and atherosclerotic plaque regression this study was done from May 2020 to October 2022, with analyses from February 2025 to January 2026 -- 104 patients with newly diagnosed sta...